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Background: Advances in research and technology coupled with an increased cancer incidence 
and prevalence has resulted in significant expansion of cancer nurse role, in order to meet the 
growing demands and expectations of people affected by cancer (PABC). Cancer nurses are also 
tasked with delivering an increasing number of complex interventions as a result of on-going 
clinical trials in cancer research. However much of this innovation is undocumented, and we 
have little insight about the nature of novel interventions currently being designed or delivered 
by cancer nurses.  
 
Objectives: To identify and synthesise the available evidence from clinical trials on interventions 
delivered or facilitated by cancer nurses. 
  
Data sources and review methods: A systematic review of randomised controlled trials (RCT), 
quasi-RCTs and controlled before and after studies (CBA) of cancer nursing interventions aimed 
at improving the experience and outcomes of PABC. Ten electronic databases (CENTRAL, 
MEDLINE, AMED, CINAHL, EMBASE, Epistemonikos, CDSR, DARE, HTA, WHO ICTRP) were 
searched between 01 January 2000 and 31 May 2016. No language restrictions were applied. 
Bibliographies of selected studies and relevant Cochrane reviews were also hand-searched. 
Interventions delivered by cancer nurses were classified according to the OMAHA System.  Heat 
maps were used to highlight the volume of evidence available for different cancer groups, 
intervention types and stage of cancer care continuum.   
 
Results: The search identified 22450 records; we screened 16169 abstracts and considered 925 
full papers, of which 214 studies (247550 participants) were included in the evidence synthesis. 
The majority of studies were conducted in Europe (n=79) and USA (n=74). Interventions were 
delivered across the cancer continuum from prevention and risk reduction to survivorship, with 
the majority of interventions delivered during the treatment phase (n=137).  Most studies 
(131/214) had a teaching, guidance or counselling component. Cancer nurse interventions were 
targeted at primarily breast, prostate or multiple cancers. No studies were conducted in brain, 
sarcoma or other rare cancer types. 
The majority of the studies (n=153) were nurse-led and delivered by specialist cancer nurses 
(n=74) or advanced cancer nurses (n=29), although the quality of reporting was poor.  
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Conclusions: To the best of our knowledge, this is the first review to synthesise evidence from 
intervention studies across the entire cancer spectrum. As such, this work provides new insights 
into the nature of the contribution that cancer nurses have made to evidence-based 
innovations, as well as highlighting areas in which cancer nursing trials can be developed in the 
future.  
Keywords: cancer care; clinical trials; interventions; nursing 
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Contribution of the Paper  
 
What is already known about the topic? 
 
 Cancer nurses play a central role in the care of patients with cancer and are the largest 
single profession working in this field.  
 Cancer nurses have employed a range of research approaches to support innovation, 
including clinical trials.  
 Trials by nurses have contributed to the evidence base for clinical innovations. 
 The complexity of cancer care, and the demand for evidence-based innovations, will 
increase with rising demand. 
 
What this paper adds 
 
 A clear summary of the current trial evidence relating to cancer nursing interventions, using 
the OMAHA classification  
 Evidence that cancer nursing interventions may be delivered at all stages of the cancer care 
continuum, but that the majority to date have focused on adults in the treatment stage 
 The majority of cancer nurse-led interventions are delivered by specialist and / or advanced 
cancer nurses, but details of interventionists are poorly described in trials 
 Cancer nurse-led trial evidence focusses primarily on mixed cancer groups, or on people 
with breast or prostate cancer, highlighting gaps for future research.    
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INTRODUCTION 
  
Cancer nurses represent the largest group of healthcare professionals providing care to people 
living with and beyond, or at risk of cancer, across all age groups and settings (WHO, 2012). 
Cancer nurses are also central to all stages of care, including screening, early detection, 
assessment, education, administration of treatments, supportive care including 
identification/management of symptoms, side-effects and complications; coordination of care, 
palliative and end of life care (Ferrell et al., 2010, Fox et al., 2017, Klemp, 2015).   Alongside 
developments in care and treatment, cancer nurses have developed a range of new roles and 
responsibilities to support people living with, beyond, or at risk of cancer. 
 
Various drivers have influenced the development of new and more autonomous nursing roles 
and functions for cancer nurses. First, contemporary cancer treatment is becoming increasingly 
complex and individualized, characterised by constant advances in therapy such as treatments 
relying on molecularly targeted agents and immunotherapies that require the adoption of a 
more personalised approach to care (Clauser et al., 2011). Second, the continuing shift from 
hospitalised cancer care to outpatient-based care has promoted the development of more 
independent roles for nurses, including symptom management and follow-up interventions 
(Bergin et al., 2016, Latter et al., 2017). Third, the specialty of cancer nursing has expanded 
rapidly, driven in part by current fiscal challenges in the global economy and a range of 
workforce pressures within the field of oncology, but also in response to the changing 
demographics and expectations of people living with, beyond, or at risk of cancer. These 
economic and political drivers have resulted in greater substitution of roles and task-shifting 
from physicians to specialized nurses with advanced and extended roles, e.g. nurse 
practitioners. 
 
Innovation and developments in cancer nursing should be underpinned by a robust evidence-
base. Furthermore, cancer nursing interventions are becoming increasingly complex, and the 
evaluation of their effectiveness necessitates significant scientific investment.  It is therefore 
important that we understand both the contribution cancer nurses make to patient care and the 
current state of trials-based evidence, in order to inform the development and evaluation of 
innovative and sustainable healthcare services and interventions.  In 2015, the European CanCer 
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Organisation (ECCO) supported an initiative to increase the recognition of the contributions 
made by cancer nursing, resulting in the Recognising European Cancer Nursing (RECaN) project. 
The first phase of this ambitious project was to conduct a systematic scoping review to 
document the interventions delivered by cancer nurses; to identify the way that cancer nurses 
have contributed to such interventions; and then to determine their effectiveness. Here, we 
present the findings of the scoping review that was the first step in this process. 
 
METHODS 
We conducted a systematic scoping review of randomised controlled trials (RCT), quasi-RCTs 
and controlled before and after studies (CBA) of cancer nursing interventions aimed at 
improving the experience and outcomes of people living with, beyond, or at risk of cancer. Our 
review was conducted to agreed methodological and reporting standards (Higgins and Green, 
2011, Liberati et al., 2009). The review analysis and inclusion criteria were specified in advance 
and documented in a protocol (Campbell et al., 2017). The review protocol is registered in 
PROSPERO (ID= CRD42016048760).  
 
Identification of studies for inclusion  
Multiple electronic databases (Medline, AMED, Epistemonikos, CINAHL, Embase, Cochrane 
Central Register of Controlled, DARE, HTA, CDSR), clinical trial registries (WHO ICTRP) from 01 
January 2000 to 30 May 2016 were searched systematically. No language restrictions were 
employed. Bibliographies of selected studies and relevant Cochrane reviews were also hand-
searched in order to identify any further relevant studies not detected by the electronic search.  
 
A comprehensive search strategy was developed, combining key terms using a series of free text 
terms and MESH terms for: profession and/role (e.g. nurse; nurse practitioner; cancer nurse; 
oncology nurse) and Cancer (e.g. neoplasm; tumour). An example search strategy is provided in 
Supplementary Table 1.  
 
Eligibility criteria 
We included RCTs, quasi-RCTs and CBAs of cancer nursing interventions delivered to participants 
screened for, diagnosed with or treated for cancer, irrespective of their age. 
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Cancer nursing interventions were defined, following a pragmatic approach, as any 
intervention(s) delivered by a nurse to a person with cancer, using the Canadian Association of 
Nurses in Oncology (CANO) definition for generalist, specialist and advanced oncology nurse 
(CANO, 2016). Such interventions could be psychological, educational, clinical or behavioural, 
provided they were aimed at people living with, beyond or at risk of cancer.  We excluded all 
studies, where interventions were aimed primarily at nurses e.g. through education, without 
any associated patient-reported outcome data. 
 
All study designs or CBA studies in which historical data was used as a comparison, but was 
collected for a different purpose at the time were excluded. We also excluded studies on any 
pharmacological or surgical only intervention, or any intervention delivered by healthcare 
professionals who are not professionally qualified nurses (e.g. support staff).  
 
Study selection 
One reviewer (PC) conducted the searching and initial screening. Two reviewers (PC, CT) 
independently applied the predefined selection criteria to the remaining records. Consensus 
meetings with a third reviewer (MW) were organised to discuss any disagreement regarding 
selection. Full publications were retrieved for studies that met the selection criteria and for 
those for which this was unclear. 
 
Data collection and management 
One review author (CT) systematically extracted key information relating to the intervention in 
accordance with the Template for Intervention Description and Replication (TIDieR) guidelines 
(i.e. procedures, intervention provider and training, mode and location of intervention delivery 
and the regime) (Hoffmann et al., 2014). A second review author (PC) checked these data and 
any disagreements that arose were resolved by discussion between the review authors. Where 
insufficient information was available, requests were sent to the original authors.   
 
Mapping and coding categories 
Following data extraction, all included studies were coded by cancer type, stage of cancer 
trajectory, care setting, level of nurse involved and nature of intervention.  
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Cancer trajectory, type and care setting 
Included studies were coded according to the stage of the cancer care continuum in which the 
intervention was delivered (i.e. prevention and risk reduction, screening, diagnosis, treatment, 
survivorship or end of life), using the cancer care continuum framework. 
 
Insert figure 1 about here 
 
Reviewers also independently coded the type of cancer using the National Cancer Research 
Institute’s Clinical Studies Groups as a guide http://csg.ncri.org.uk/groups/clinical-studies-
groups/ . This included 15 possible codes: advanced cancer, bladder and renal (including penile), 
brain (includes CNS), breast, colorectal/anus, gynaecological, haematological oncology 
(leukaemias and myeloma), head and neck, lung, lymphoma, prostate, sarcoma, skin cancer, 
testis, upper gastro-intestinal (includes neuroendocrine). Where more than one type of cancer 
was described, reviewers classified this as ‘multiple’. Studies that screened participants for 
cancer were coded separately. 
 
Studies were also coded according to the setting of care e.g. hospital inpatient or outpatient 
setting, home or primary care setting.    
 
Level of Nurse 
Three reviewers with content expertise (UO, EP, TW) coded the level of nurse responsible for 
delivering the intervention using the CANO classifications of generalist, specialist and advanced 
nurse (CANO, 2016). 
 
Classification of interventions 
A series of team discussions were held to reach consensus on methods for grouping 
interventions from the included studies into relevant categories. Using an iterative process, 
involving discussion between pairs or groups of review authors with expertise relating to cancer 
nursing (MW, UO, EP, ME, LS, ML, CO, MS, CF, WO), an agreement was reached to use the 
categories proposed by the OMAHA nursing intervention classification as these were deemed 
more relevant to the aim of this review (OMAHA, 2016, Topaz et al., 2014). 
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This classification system includes four core categories: 
1. Case Management 
2. Surveillance 
3. Teaching, Guidance, and Counselling 
4. Treatments and Procedures 
 
Two independent reviewer pairs were asked to consider both the nature of the role taken by the 
nurse in the intervention as well as what the intervention actually was. Table 1 summarises the 
different OMAHA categories and approaches agreed a priori by the reviewers when coding the 
interventions.  Many interventions were complex and included a number of different 
components.  In these cases, they were classified according to the OMAHA category which best 
encompassed the nature of the intervention.  Any disagreements between reviewer pairs were 
resolved by a third reviewer.  The methodological application of the OMAHA categories, tasks 
and components for the classification of cancer nursing will be published in more detail 
elsewhere.  
 
Data synthesis 
Data from all included studies were synthesised within evidence tables and narrative, 
categorised according to OMAHA categories. Heat maps were generated in Excel (Microsoft). 
Conditional formatting was employed and those values with the highest frequency were 
assigned a red colour, middle values a yellow colour and lowest values a green colour.  
 
RESULTS 
Results of the search 
Our searching identified 22450; screened 16169 abstracts and considered 925 full papers. 
Results of the search are displayed in Figure 1. Of the 925 potentially relevant studies, 518 
studies were excluded. Reasons for exclusion were primarily due to inadequate description of 
the interventionist, or the intervention did not include a cancer nurse or the study design failed 
to meet selection criteria. We identified 83 studies as on-going (i.e. published protocols or on-
going trials) and 18 studies as awaiting assessment (i.e. studies requiring translation or missing 
information sought but not available or full text papers were unavailable), leaving 316 reports of 
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214 unique studies that were eligible for inclusion within the narrative synthesis (Supplementary 
Tables 2 – 5) (Figure 1).  
 
Description of included studies 
We included a total of 214 studies (247550 participants) in this review. Geographical locations of 
the included studies are shown in Supplementary Tables 2 –5. The majority of studies were 
conducted in Europe (n=79) or USA (n=74). Of the 214 included studies, 153 were nurse-led and 
61 studies were nurse-facilitated (meaning that they were delivered by cancer nurses, as part of 
a wider multidisciplinary team).  
 
The distribution of OMAHA heat map categories across all the included studies for cancer type is 
shown in Figure 2 and data are presented by trajectory in Figure 3.  The greatest number of 
studies focused on teaching, guidance and counseling interventions in patients with multiple 
(two or more types) cancers and those with breast and prostate cancer.  Studies on rare cancers 
were scarce.   
 
 
 
Intervention descriptions 
 
In the following section, a brief overview of the interventions categorised according to the 
OMAHA nursing intervention classification is given: 
1. Case management (n=38) (Supplementary Table 2) 
2. Surveillance (n= 27) (Supplementary Table 3) 
3. Teaching, counselling and guidance (n=131) (Supplementary Table 4)   
4. Treatment and procedures (n = 18) (Supplementary Table 5) 
 
Case management 
Thirty-eight studies (57193 participants) were categorised as case management, most 
commonly employing a parallel RCT design (n=26). The sample size varied across studies from 20 
– 49311 participants. Most studies included 101 – 500 participants (n=27). Case management 
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studies involved adult (or older adult) participants in 37 studies; only one trial included a mixed 
population of people with cancer and their carers (Supplementary Table 2). 
 
Over half of the studies in this category included participants with a range of different cancer 
types (classed as ‘multiple’) (n=20) (Supplementary Table 2, Figure 2). The majority of these 
studies were focused on the phase of cancer treatment (n=20) and end-of-life (n=12) (Figure 3).  
 
The most common focus of case management interventions was the provision of supportive 
care or psychosocial and/or psychosexual care. Other common components of these 
interventions were the management of signs and symptoms, primarily emotional and continuity 
of care (Supplementary Table 2). Specialist oncology nurses (n=13) or advanced cancer nurses 
(n=12) delivered the majority of interventions (n=23), however a variety of descriptors were 
used to document their professional roles, education and training (Supplementary Table 2, 
Figure 4). 
 
The number of contacts for delivering case management interventions were clearly reported in 
23 studies and ranged from 1- 18 contacts (face-to-face and telephone), Supplementary Figure 
5a. The length of interventions ranged widely from 1.5 to 260 weeks (Supplementary Figure 5b). 
The amount of time attributed to case management interventions delivered by cancer nurses 
ranged from 120 to 1377 minutes per participant (Supplementary Table 2).  
 
Surveillance 
Twenty-seven studies (4892 participants) were included in the surveillance category.  All of the 
participants were adults. Sample size ranged from 43 – 775 participants. Six studies included less 
than 100 participants with the majority of studies (n=21) including between 101 – 500 
participants. 
 
The majority of studies in this category focused on women with breast cancer (n=8). Over half of 
the interventions in 16/27 studies were delivered in the treatment phase of the cancer 
trajectory. However, a third of studies classed as surveillance interventions (9/27) took place in 
the survivorship phase. The descriptions of components involved interventions aimed at 
assessment, managing signs and symptoms, encouraging self-management and supportive care. 
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Specialist nurses delivered the majority of surveillance interventions; however once again a 
variety of descriptors were used to document their professional education and training (Figure 
4, Supplementary Table3) 
 
All of the interventions were delivered on a 1-to-1 basis. Most studies included face-to-face and 
telephone contact; 8 were telephone interventions only (no face-to-face contact) and 4 had 
additional e-health / computer delivered components. Interventions were mainly delivered in an 
outpatient or home based environment. The intervention regime varied across studies from 1 to 
25 sessions; total amount of time attributed to the interventions ranged from 30 to 675 mins 
(n=14 studies) and was delivered over 1 week to 260 weeks (Supplementary Figure 5a-b, 
Supplementary Table 3). 
 
Teaching, guidance and counselling 
The majority of studies were categorised as teaching, guidance and counselling (n=131; 182075 
participants). Although most of the studies were conducted with adults, 15/131 had a mixed 
population, including people with cancer and their partners (n=9/16), or people with cancer and 
Health Care Personnel (HCP - 6/16); 1/16 included family members, HCP and people with 
cancer. Five studies in this category included children and young people as participants. The 
sample size across studies ranged from 18 – 138392 participants, with most studies ranging 
between 101 – 500 participants (n=62). Studies on screening recruited the highest number of 
participants. The interventions in this category were delivered to people with multiple types of 
cancer (n=45) but women with breast cancer (n=34) and men with prostate cancer (n=13) also 
received teaching, guidance and counselling interventions (Figure 2). Interventions in this 
category were delivered across the entire cancer care continuum with the majority delivered in 
the treatment phase of the cancer trajectory (86/131) (Figure 3). 
 
The main components of the interventions delivered in this category comprised of education 
and provision of psychosocial and psychosexual support or helping people with cancer manage 
symptoms (e.g. pain management, fatigue). Other interventions focused on exercise, genetics 
and activities aimed at promoting self-management and self-care (Table 4). 
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Although cancer nurses delivered the majority of interventions; details reporting their education 
and training were often vague, describing nurses as “experienced’ or “trained’; with details of 
education unreported in over a third of studies (n=52/131) (Supplementary Table 4). 
 
Where reported most interventions were provided in broadly similar settings to those described 
in other intervention categories. Most interventions were provided on an individual and face-to-
face basis; although a number of trials delivered the intervention in a group setting. Intervention 
regime varied across studies from 1 to 18 sessions (or contacts); total amount of time attributed 
to the interventions ranged from 3 to 1260 minutes delivered over 1 week to 104 weeks. 
 
Treatment and procedures 
Eighteen studies (3390 participants) were included in the treatment and procedures OMAHA 
category.  The majority of studies were conducted with adults (n=14); 3 studies included 
children and young people only. Sample size varied across studies from 7 – 844 participants. The 
majority of studies (11/18) included less than 100 participants. Five out of the eighteen trials 
included participants with a range of different cancer types (i.e. interventions were delivered to 
‘multiple’ disease groups) (Supplementary Table 5). Interventions in 15/18 studies were 
delivered in the treatment phase of the cancer trajectory. 
 
The main components of the interventions delivered in this category comprised screening 
procedures (e.g. endoscopy or colonoscopy), interventions targeting signs and symptoms in 
people affected by cancer using techniques such as massage, Hickman line insertions or decision 
algorithms. Other interventions focused on medication administration (Supplementary Table 5) 
and activities aimed at improving physical care including exercise and lymphatic drainage in 
women with breast cancer. Specialist cancer nurses delivered the intervention in 4 studies, but 
the education and training details in the majority of this category (n=10) were unclear (Figure 4). 
 
Most interventions were provided on an individual and face-to-face basis. Where reported, the 
interventions were provided primarily in the hospital setting and were delivered in single session 
(n=9) (Table 6). However, the amount of time attributed to the interventions varied widely 
across studies from a single (brief 15 minute) intervention to more time intensive intervention 
of 21 sessions delivered over 72 weeks (Supplementary Figure 5a-b).  
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DISCUSSION 
 
Key findings 
Our review presents evidence of cancer nurses being actively engaged in a large number of 
trials, delivering complex, often very diverse, interventions across the entire cancer spectrum. 
Interventions were often multifaceted, with the majority of interventions targeting people living 
with cancer during the treatment phase, and delivered in a variety of settings. Interventions 
included direct care, psychological support, teaching, assessment and monitoring, care 
management and coordination, and were delivered face-to-face; via telephone and online; to 
individuals and groups. The interventions varied in duration and intensity with the majority 
requiring between 1-6 sessions (contacts), delivered over 13 – 26 weeks, and therefore 
consumed a significant time resource for nurses.  In the context of a rapidly developing evidence 
base, the multidimensional role played by cancer nurses in studies documented in this review, 
covers all aspects of the ICN definition of nursing (ICN, 2002), providing the first broad picture of 
cancer nursing interventions delivered within clinical trials.  
 
The majority of interventions in this review were nurse-led, but cancer nurses also clearly 
facilitated a number of interventions as part of a wider team. With multi-professional teams, 
consisting of medical, nursing, allied professionals, and diagnostic experts, now firmly 
established at the heart of cancer care (Taylor et al., 2013), cancer nurses can be seen to have 
established a core co-ordination role within these teams by acting as the patient’s key worker 
and thereby a consistent point of reference through the care pathway (Lafferty et al., 2011). As 
the context of healthcare delivery is changing rapidly, with greater outpatient care and more 
emphasis on self-management for the increasing number of people living with and beyond 
cancer, the need for innovation in nursing is increasing (Macmillan Cancer Support, 2014).  For 
some years, nurses have taken on novel and more autonomous roles (Cancer Services 
Collaborative Improvement Partnership, 2005), a situation set against a landscape of an 
increasingly pressured financial climate, and in the context of a global shortage of nurses. 
(Beans, 2016, Lancet Oncology, 2015). Understanding the nature, breadth and effectiveness of 
such roles, and the innovations that they have championed as described here, may help support 
the case for investment in what is an increasingly scarce nursing resource. Healthcare 
organizations are now having to deal with competing and complex demands, and the need for 
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effective cancer care, alongside other chronic diseases, exists in a context of rising expectations 
to deliver more with the same, or even fewer resources.  This review indicates where research 
attention has been paid to innovations in nursing in cancer care, and where gaps still exist.  
 
The majority of trials in this review recruited adults; we identified few studies involving children 
and adolescents or young adults. Furthermore, most studies recruited patients with two or 
more types of cancer; fewer studies focused solely on people diagnosed with a single cancer 
type (i.e. breast, prostate and colorectal/anus cancer). The review identified no nurse-led or 
nurse-facilitated studies in people diagnosed with brain, bladder and renal, skin cancer, 
sarcomas and testis cancers.  The lack of studies in these areas could be explained by the type of 
study design criteria in our review, and it is likely that other study designs (e.g. qualitative 
studies) with fewer ethical barriers may have explored the experiences of these groups and 
people diagnosed with other ‘rarer’ cancers in more detail. Importantly, our review highlights a 
gap in the current evidence base, suggesting a need for more evidence in these disease groups, 
and high quality cancer nursing trials across all groups.  
 
Cancer nursing interventions were delivered across the continuum from prevention and risk 
reduction to survivorship. Most interventions were delivered during the treatment and 
survivorship phases. Fewer interventions were delivered during the diagnostic phase.  This was a 
surprising finding as an increasing body of literature strongly supports the presence of a nurse 
during the diagnosis of cancer (Gilbert et al., 2011, Mertz et al., 2017). Perhaps less surprisingly, 
the majority of cancer nursing interventions in this review were classified as teaching, guidance 
and counselling interventions, with fewer interventions focused on case management, 
surveillance or treatment.  Cancer nurses have traditionally had a significant role to play in 
supporting patients through information provision, education and psychological support, but are 
also increasingly engaged in delivering complex treatments, undertaking diagnostic procedures, 
leading follow-up and survivorship care and managing treatment pathways.  Robust evidence to 
underpin these interventions is urgently needed.   
 
As most trial interventions were delivered by specialist or advanced cancer nurses this has clear 
implications for education and workforce planning. This finding supports the benefits gained 
from providing a robust career structure for cancer nurses, with relevant education, that 
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promotes research skills underpinned by the necessary mentoring and support. The demands 
likely to be placed on cancer services in the future suggest that effective and affordable nurse-
led interventions are going to be required in greater numbers to meet the needs of different 
cancer groups (Kelly and Charalambous, 2017, NHS, 2017).  Comprehensive education, training 
and support for cancer nurses is needed in order for them to take on more flexible roles, and to 
extend their competency, in both practice and research, across the cancer care continuum 
(EONS, 2018, RCN, 2017).    
 
There are also a number of implications for research and practice. The quality of reporting of 
trials of cancer nursing interventions could be significantly improved.  For example, in this 
review nurse trialists often failed to report on interventionist details adequately (e.g. 
qualifications and training) in 40% of the included studies. Journals should encourage trialists to 
provide full descriptions and profiles of the interventionists as well as the interventions 
themselves (Wells et al., 2012), using recent reporting guidelines (TiDIER) (Hoffmann et al., 
2014). Such detail is essential if we are to capture all interventions delivered by cancer nurses 
and to understand the full extent (and impact) of cancer nursing involvement in trials, as well as 
implementing new evidence into practice.  Additionally, there is a need for more robust 
research from countries and healthcare contexts across Europe and further afield.  Investment 
in collaborations to build international studies is a crucial step if we are to build a contextually 
meaningful and convincing evidence base for interventions that are led or delivered by cancer 
nurses.      
 
 
Strengths and Limitations 
The study has a number of strengths and limitations. While we are confident we have identified 
most published trials of relevance to the review it is possible, despite our best efforts, that we 
may be unaware of additional work. For example, we were unable to include a number of trials 
because details of the interventionist were not reported, or were reported only poorly. 
Although we contacted the original authors where possible, some data pertaining the reviewed 
studies were unavailable.  
 
The use of the OMAHA classification system (OMAHA, 2016, Topaz et al., 2014), although a 
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widely employed measure to categorise general nursing interventions, may have oversimplified 
the scope of some interventions.  However, we are unaware of any cancer nursing-specific 
intervention classification systems. An area that has not received adequate attention in the 
reviewed studies, nor has been captured in this review, is the question of translational impact 
by findings being taken up in practice. Whether, and to what extent, these trials have led to the 
greater implementation of cancer nursing interventions, especially in other practice settings, 
remains unknown.  
 
Furthermore, the degree to which these findings support the call for upskilling cancer nurses in 
specific areas of practice has not been established. It is, however, likely that the interventions 
evaluated in the 214 trials in this review, represent only a fraction of those actually delivered by 
cancer nurses internationally.  We also acknowledge that the scoping review is based on trials 
published between 2000 and 2016 only, and that historical as well as more recent papers may 
have added to the body of knowledge presented here.  
 
Previous reviews of cancer nursing interventions have focused solely on one type of 
intervention, or type of cancer (Campbell et al., 2017). Despite acknowledged limitations, this 
review provides the first comprehensive picture of the cancer nurse interventions that have 
been introduced and trialled across clinical settings, at different points of the cancer trajectory, 
and aimed at diverse cancer populations.  
 
Conclusion 
Our review has clearly captured the breadth and scope of cancer nurses in delivering 
interventions within a trial design. Cancer nurses are performing multiple and increasingly 
complex roles in a variety of settings across the care continuum. The roles are diverse, requiring 
considerable expertise in many specialist areas of clinical cancer care, in addition to research 
skills. This review provides novel insights to enhance our current understanding of cancer 
nurses’ evolving roles as trialists, and identifies the focus, to date, for the delivery of complex 
interventions by cancer nurses. As such, it forms the basis of an ongoing dialogue that we hope 
will transform awareness of the extent and level of contribution that cancer nurses are making 
to improve cancer care. In an era of distributed knowledge and search for cost-effective 
innovation to meet demand we suggest that the contribution of cancer nursing should be better 
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recognized. Whilst the review has clear relevance to the European context, having been 
conducted by members of the European Oncology Nursing Society, we suggest that these 
findings also have global currency given the rising demand now being placed on cancer services 
around the world.   
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Figure 1. PRISMA Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records identified through 
database searching 
(n = 21038) 
Sc
re
e
n
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Additional records identified 
through other sources 
(n = 1412) 
Titles screened  
(n=22450) 
Abstracts screened 
(n = 16169) 
Records excluded 
(n = 15244) 
Full-text articles assessed 
for eligibility 
(n = 925) 
Full-text articles excluded, 
with reasons 
(n = 513) 
[Design did not meet criteria 
(n=383); Inadequate 
information about 
interventionists or did not 
include a cancer nurse 
(n=99); no patient reported 
outcomes e.g. caregiver or 
nurse outcomes only (n=31) 
Studies awaiting assessment 
(n=18); 
Ongoing studies (n=83) 
Studies included in 
narrative synthesis 
(n =214 trials reported 
across 311 papers) 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 25 
Figure 2. The distribution of OMAHA heat map categories across all the included 
studies (n=214) for cancer type. Values with the highest frequency were assigned a red 
colour, middle values a yellow colour and lowest values a green colour. 
 
 
Case 
Management 
Surveillance 
Teaching, 
Guidance, 
and 
Counselling 
Treatments 
and 
Procedures 
Total 
Advanced cancer 
(not specified) 
3 1 3 0 
7 
Bladder & Renal 
(includes penile) 
0 0 0 0 
0 
Brain (includes 
CNS) 
0 0 0 0 
0 
Breast 5 8 34 3 50 
Colorectal/anus 2 5 5 3 15 
Gynaecological 3 2 1 0 6 
Haematological 
Oncology  
0 0 4 2 
6 
Head & Neck 0 3 2 0 5 
Lung 3 2 4 1 10 
Lymphoma 0 0 1 1 2 
Prostate 0 1 13 1 15 
Sarcoma 0 0 0 0 0 
Skin Cancer 0 0 0 0 0 
Testis 0 0 0 0 0 
Upper GI 0 0 1 0 1 
Multiple 20 5 45 5 75 
S&P 2 0 18 0 20 
NR 0 0 0 2 2 
Total 38 27 131 18 214 
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Figure 3. (A) The distribution of OMAHA heat map categories plotted across all the 
included studies (n=214) for cancer trajectory. (B) OMAHA heat map categories 
plotted by participant numbers within each study for each stage of the cancer 
continuum. Values with the highest frequency were assigned a red colour, middle values a 
yellow colour and lowest values a green colour. 
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(B) 
Case 
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Treatment 
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Total 
Prevention and 
Risk reduction 
0 0 2873 0 
2873 
Screening 49458 0 158279 1725 209462 
Diagnosis 0 0 97 0 97 
Treatment 4706 3044 16405 1665 25820 
End-of-life 2422 248 106 0 2776 
Survivorship 607 1600 4315 0 6522 
Total 57193 4892 182075 3390 247550 
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Figure 4. Bar graph showing the level of nurse interventionist using the CANO 2016 descriptors.  
Key: ADV: advanced, CM: case management intervention category; GEN: general nurse, SPEC: 
specialist nurse; SURV: surveillance intervention category; TGC: teaching, guidance and 
counselling intervention category; TP: treatment and procedure intervention category; UNC: 
unclear; >1 type (more than one type of nurse included in the study) 
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Table 1. Criteria for classification of interventions using the OMAHA core categories  
OMAHA 
category 
OMAHA description Additional descriptors guiding decisions made by 
the RECaN team 
Case 
Management 
Activities such as coordination, 
advocacy, and referral that facilitate 
service delivery, improve 
communication among health and 
human service providers, promote 
assertiveness, and guide the 
individual/family/community toward 
use of appropriate resources. 
 
Interventions which involved a variety of 
coordinated activities were classified here, 
including, for example, most palliative home care 
interventions.  Other nurse-led interventions which 
involved teaching and support, monitoring 
symptoms or medications and liaising with other 
health professionals (i.e. were a combination of all 
four core categories or described a stepped care 
approach involving a range of interventions) were 
coded as case management.   
 
Surveillance Activities such as detection, 
measurement, critical analysis, and 
monitoring intended to identify the 
individual/family/community's 
status in relation to a given 
condition or phenomenon. 
 
Interventions described as nurse-led follow up 
were usually coded to this category, however, 
where it was clearly described that the 
intervention involved complex co-ordination of 
care and symptom management and a range of 
different activities we coded this to CASE 
management. 
Interventions directed at assessing and/or 
monitoring symptoms, providing tailored advice for 
those symptoms, reporting back to oncologists etc 
were also categorised here. 
 
Teaching, 
Guidance, 
and 
Counselling 
Activities designed to provide 
information and materials, 
encourage action and responsibility 
for self-care and coping, and assist 
the individual/family/community to 
make decisions and solve problems 
Where the intervention was described as an 
educational or counselling intervention and where 
teaching, providing information or psychosocial 
support were the primary focus, and these were 
provided using a structured protocol and for a 
specific aspect of care, we used this category. We 
included CBT interventions and those directed at 
equipping carers to manage care in this category. 
Interventions targeted at improving specific 
symptoms e.g. fatigue, through a mixture of 
education, teaching exercise and strategies were 
also included here.  However, if the intervention 
involved education AND symptom assessment, 
management, coordination of care and other 
specialists, with a particular nurse-led focus we 
used the category CASE Management.  If the 
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intervention was primarily symptom focussed and 
included changing or administering medication it 
was classified as TREATMENT. However, if it was 
primarily symptom focussed and mainly about 
assessment and tailored advice /intervention for 
that symptom it was classified as Surveillance. 
Treatments 
and 
Procedures 
Technical activities such as wound 
care, specimen collection, resistive 
exercises, and medication 
prescriptions that are designed to 
prevent, decrease, or alleviate signs 
and symptoms of the individual/ 
family/ community. 
Under this category we included interventions 
where the nurse provided a treatment or was 
responsible for a specific procedure, including 
massage, diagnostic procedures such as 
endoscopy, or for managing medication. 
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